

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 31 of March 201

	31.03.2021	31.12.2020
	BGN'000	BGN'000
ASSETS		
Non-current assets		
Property, plant and equipment	36 392	37 123
Intangible assets	3 784	3 816
Assets with usable assets	158	210
Trade receivables	5 176	5 176
Total non-current assets	45 510	46 325
Current assets		
Inventories	9 967	10 842
Trade and other receivables	64 271	60 084
Current corporate income tax	-	14
Treasury shares redeemed	-	1
Cash and cash equivalents	28	45
Total current assets	74 266	70 986
Total assets	119 776	117 311
LIABILITIES		
Equity		
Share capital	82 200	82 200
Reserves	12 032	12 032
Retained earnings	5 958	2 904
Total	100 190	97 136
Non-current liabilities		
Long-term loans	2 104	1 731
Deferred tax liabilities	1 139	1 139
Retirement benefit obligations	194	194
Total non-current liabilities	3 437	3 064
Current liabilities		
Trade and other liabilities	5 430	6 583
Short-term loans	9 782	9 783
Current portion of long-term loans	492	541
Current corporate income tax		
Other tax liabilities	445	204
Total current liabilities	16 149	17 111
Total liabilities	19 586	20 175
Total equity and liabilities	119 776	117 311

Date of preparation: 23.04.2021


Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/



Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 31 of March 2021

	31.03.2021	31.03.2020
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	13 386	10 848
Other income	2	52
Total income	13 388	10 900
Carrying amount of goods sold	(147)	(145)
Changes in inventories of finished products and work in progress	332	(150)
Materials and services	(7 787)	(6 285)
Personnel expenses	(1 345)	(1 099)
Depreciation / amortisation expenses	(1 072)	(1 021)
Other expenses	(199)	(42)
Finance income	1	14
Finance costs	(103)	(103)
Total expenses	(10 320)	(8 831)
Profit before taxation	3 068	2 069
Corporate income tax expense	(14)	(90)
Profit/Loss for the period	3 054	1 979
Total comprehensive income for the period	3 054	1 979
Earnings per share / in BGN per 1 share /	0.04	0.02

Date of preparation: 23.04.2021

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/



Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 31 of March 2021

	31.03.2021	31.03.2020
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	8 344	8 194
Payments to suppliers of materials, goods and services	(5 954)	(5 109)
Payments to personnel	(1 319)	(1 041)
Foreign exchange gains and losses	(4)	(8)
Payments of interest and dividends		(232)
Other proceeds / payments	(495)	(990)
Net cash flows	572	814
Cash flows from investing activities		
Payments on non-current assets acquired	(540)	(559)
Net cash flows	(540)	(559)
Cash flows from financial activities		
Proceeds from loans	33	33
Payments on loans	(33)	(81)
Payment of interest, dividends	(50)	
Payments on finance lease		(104)
Other proceeds/payments from treasury shares	1	
Net cash flows	(49)	(152)
Change in cash and cash equivalents	(17)	103
Cash and cash equivalents at the beginning of the period	45	40
Cash and cash equivalents at the end of the period	28	143

Date of preparation: 23.04.2021

Sofia


Prepared by:.....

/ P. Moneva /

Executive

Director:.....

/B. Georgiev /



Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 31 of March 2021

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2020	82 200	4 099	7 676	2 568	96 543
Profit/loss for the period				604	604
Other comprehensive income		(11)			(11)
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		(11)		604	593
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			268	(268)	
Total amount of income and expenses recognised during the period			268	(268)	
Balance as of 31.12.2020	82 200	4 088	7 944	2 904	97 136
Balance as of 01.01.2021	82 200	4 088	7 944	2 904	97 136
Profit/loss for the period				3 054	3 054
Other comprehensive income					
Total comprehensive income				3 054	3 054
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period					
Balance as of 31.03.2021	82 200	4 088	7 944	5 958	100 190

Date of preparation: 23.04.2021
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev /

